Picture of InnovAge Holding logo

INNV — InnovAge Holding News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

InnovAge's Q2 revenue rises

Overview

Healthcare provider's fiscal Q2 revenue grew 14.7%, beating analyst expectations

Net income for fiscal Q2 reached $11.8 mln, compared to a loss last year

Adjusted EBITDA for fiscal Q2 rose significantly, reflecting improved operational performance

Outlook

InnovAge raises full-year fiscal 2026 revenue guidance to $925 mln-$950 mln

Company expects full-year adjusted EBITDA of $70 mln-$75 mln

InnovAge maintains ending census guidance at 7,900-8,100 participants

Result Drivers

REVENUE GROWTH - Revenue increased 14.7% due to disciplined execution and a focus on clinical outcomes, according to CEO Patrick Blair

PARTICIPANT INCREASE - Participant census rose to approximately 8,010, up from 7,480, contributing to revenue growth

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 RevenueBeat$239.70 mln$228.26 mln (3 Analysts)
Q2 EPS$0.08
Q2 Net Income$11.8 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell" Wall Street's median 12-month price target for InnovAge Holding Corp is $7.00, about 22.8% above its February 2 closing price of $5.70 The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago Press Release: ID:nGNX1zMcLy For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on InnovAge Holding

See all news